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BACKGROUND: According to the theory of endothelial dysfunction, the pathogenesis of preeclampsia is associated with the imbalance of 
angiogenic and anti-angiogenic factors.  Transforming 
growth factor-beta 1 (TGF-β1) has also proposed as a pro-
angiogenic factor that influences preeclampsia. This study 
was conducted to compare a mean difference of TGF-β1 
between preeclampsia and normal pregnancy.
METHODS: This study was an observational cross-
sectional study with 25 subjects of pregnant women with 
preeclampsia and 25 subjects of normotensive pregnant 
women. The study was conducted in Dr. Reksodiwiryo 
Hospital, Bhayangkara Hospital, and Dr. Rasidin Hospital 
in Padang, Indonesia from October 2015 to January 2016. 
For the determination of TGF-β1 concentration, peripheral 
Abstract venous blood samples were taken. The blood samples were 
analyzed by enzyme-linked immunosorbent assay (ELISA) 
in Biomedical Laboratory, Faculty of Medicine, Andalas 
University. The mean difference was statically analyzed by 
independent samples T-test.
RESULTS: The mean difference of TGF-β1 was lower 
in preeclampsia group than normal pregnancy group 
(2.02±0.99 ng/mL vs. 3.24±2.67 ng/mL; p<0.05).
CONCLUSION: The TGF-β1 concentration was lower in 
pregnant women with preeclampsia. Thus, it may have a 
role as a marker in preeclampsia.
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Introduction
Preeclampsia is a major complication in pregnancy and 
a leading cause of death and also maternal and perinatal 
morbidity. Globally, 10-15% of maternal deaths are directly 
related to preeclampsia and eclampsia. According to 
WHO, preeclampsia/eclampsia is the second leading cause 
of morbidity and mortality in pregnant women.(1) The 
incidence of preeclampsia is different in each country, it 
ranges between 2-8% of all pregnancy.(2)
 Preeclampsia/eclampsia is still called a disease of 
theory.  Various  studies have not been able to explain 
precisely  the exact cause of the disease. According to 
the theory of endothelial dysfunction, the pathogenesis 
of preeclampsia is associated  with  angiogenic  and 
anti-angiogenic factors. The imbalance in both of these 
factors will   affect trophoblast  invasion  and spiral artery 
remodeling.(3) Angiogenic and anti-angiogenic protein have 
been widely studied in pregnant women with preeclampsia. 
The concentration of angiogenic and anti-angiogenic factors 
of mother  plasma/serum has been proposed as a parameter 
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that can  help  to  identify women with preeclampsia 
potential.(4)
 Angiogenic  protein that  has widely known is vascular 
endothelial growth factor (VEGF). Soluble fms-like  tyrosine 
kinase-1 (s-Flt-1) is  a  protein  antagonist  which  is  able  to 
decrease  the vasodilatation  by  reducing  the level  of free 
circulating VEGF that can lead to hypertension.(5) Besides 
VEGF, transforming growth factor-beta 1 (TGF-β1) have 
also proposed as a pro-angiogenic factor that influences 
preeclampsia.(6)  TGF-β  family  plays  a  role  in  the 
endothelial cell growth and angiogenesis, affect the nature 
of immune responses and can affect various functions of 
trophoblasts.(7) 
 The previous studies had reported inconsistent results 
about  the association of TGF-β1 with preeclampsia. 
Hennessy,  et al., stated  that  there  were  no  differences 
in  the  levels  of  TGF-β1  in  high-risk  pregnant  women 
that  ended  with preeclampsia  and  normal  pregnant 
women.(8) Meanwhile, another study showed that TGF-β1 
was significantly lower in the preeclamptic group than in 
normal pregnancy.(9) In another side, Enquobahrie, et al., 
reported that Zimbabwe women with preeclampsia tend to 
have a higher TGF-β1 than normal pregnant women.(10) 
The possibility of TGF-β1 as a marker for preeclampsia and 
the inconsistent results which were found in the previous 
studies have intrigued the writers to study the differences in 
mean serum levels of TGF-β1 in the preeclamptic patients 
and normal pregnancies.
This was an observational study with a cross-sectional 
design. This study conducted from October 2015 to January 
2016 and was approved by The Committee of Medical 
Research Ethics of Dr. M. Djamil Hospital. The population 
was the pregnant women after 20-week gestations in maternal 
ward and clinic of Dr. Reksodiwiryo Hospital, Bhayangkara 
Hospital, and Dr. Rasyidin Hospital in Padang, Indonesia. 
A total of 50 subjects were included in this study and were 
took by consecutive sampling. The pregnant women after 
20-week gestations, who diagnosed as preeclampsia (25 
subjects) and normal pregnancy (25 subjects), were willing 
to follow this research, and had a singleton pregnancy, were 
included in this study. Meanwhile, the exclusion criteria were 
subject with systemic inflammation (leukocytes >16,000 
µL), multiple pregnancies, and history of diabetes mellitus, 
dyslipidemia, kidney, or heart disease. The gestational age 
was matched in the two groups.
Methods
 After providing informed and agree to participate in 
this study by written consent, 3 mL of peripheral venous 
blood samples were collected from antecubital vein to 
analyze the TGF-β1 concentration. The blood then stored 
in the cool box and sent to the Biomedical Laboratory, 
Faculty of Medicine, Andalas University immediately 
to be centrifuged for 10-15 minute. The separated serum 
then was brought to the laboratory to analyze the TGF-β1 
concentration by using enzyme-linked immunosorbent 
assay (ELISA) method with Elabscience TGF-β1 ELISA 
Kit (Elabscience, Hubei, China). 
 Normality test was analyzed by Shapiro-Wilk test. 
The Independent samples t-test then used to determine the 
significant difference. Statistical analysis was conducted 
using the SPSS ver 22.0.Results
The subject characteristics are presented in Table 1. The 
age, parity, body mass index, hemoglobin, and leukocytes 
of the subjects were higher in women with preeclampsia 
than in women with normal pregnancy. As shown in Table 
2, the mean concentration of serum TGF-β1 was lower in 
preeclampsia than normal pregnancy (2.02±0.99 ng/mL vs. 
3.24±2.67 ng/mL; p<0.05). Discussion
Our study found the mean concentration of serum TGF-β1 
was lower in preeclampsia than normal pregnancy (p<0.05). 
Our study result was in accordance with the systematic 
review study in eight case-control studies which concluded 
the TGF-β1 concentration was significantly lower in 
preeclampsia group in the second trimester but significantly 
higher in the third semester.(9)  Clausen, et al., found 
that there was a significantly lower concentration level of 
TGF-β1 in women with eventual preeclampsia, compared 
to the controls healthy pregnant women (3.2 ng/mL vs. 5.3 
ng/mL; p=0.01).(11) Our study was also in accordance with 
a study by Lim, et al., which found that TGF-β1 were lower 
in preeclampsia group (p<0.001).(12)
 The previous study found that there was an imbalance 
between the placenta pro-angiogenic and anti-angiogenic 
factors in preeclampsia which may harm vascular 
endothelial and make the clinical symptoms of the mother. 
The existence of TGF-β1 as a pro-angiogenic factor in 
pregnancy, are needed to assist in the maturation of blood 
vessels in the placenta.(5)
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Preeclampsia Normal Pregnancy
Mean±SD Mean±SD
Mother Age (year) 32.2±3.9 30.6±4.5 0.201
Gestational Age (week) 37.9±1.0 37.6 ±0.94 0.319
Parity 2.3±1.5 2.04±1.36 0.497
Body Mass Index (kg/m ) 23.9±2.0 22.7±2.19 0.0572
Hemoglobin (g/dL) 11.1±0.9 10.5±1.20 0.064
Leukocytes (/µL) 12222±2619 8228±1449 0.000
*p values are obtained by independent t-test. 
  Body Mass Index before pregnancy
p  value*
#
#
Preeclampsia Normal Pregnancy
Mean±SD Mean±SD
TGF-β1 (ng/mL) 2.02±0.99 3.24±2.67 1.22 (2.38-2.54) 0.041
#
#
p  value*
*p values are obtained by independent t-test. 
  Body Mass Index before pregnancy#
Mean Difference 
(95%CI)
Table 1. The subject characteristics of the study.
Table 2. Comparison of TGF-β1 in preeclampsia and normal pregnancy.
 In preeclampsia, there is disruption of trophoblast 
invasion in the spiral arteries that result in the destruction 
spiral arteries which cause the decreasing blood flow 
in the intervillous space. The decreasing uteroplacental 
blood flow can cause placental hypoxia that may lead to 
the release of toxic substances such as cytokines (tumor 
necrosis factor (TNF)-α, interleukin (IL)-6) as a reaction to 
the inflammatory response and increased anti-angiogenic 
factors such as soluble endoglin (sEng) and s-Flt-1. 
Increased sEng anti-angiogenic factors will alter the process 
of interaction between TGF-β1 and its receptors (Eng) and 
can make TGF-β1 decreased. This will inhibit angiogenesis 
and apoptosis that causing endothelial dysfunction.(13) 
Another theory was that the inhibition of normal TGF 
signaling by sEng played a role in placental dysfunction 
secondary to vascular damage that can lead to placental 
hypoxia and increased production of s-Flt-1 and sEng.(14)
 Although sEng has been suggested to be a biomarker 
of the severity of preeclampsia, the association of TGF-β1 
with preeclampsia was still conflicting nowadays. A study in 
Peruvian  women  found  the  TGF-β1  concentration  were 
42% higher in cases than in control (18.4±1.0 ng/mL vs. 
13.0±0.8 ng/mL, p<0.001).(15)  It is relevant with a study 
by Naicker, et al., which reported that TGF-β1 significantly 
increased in plasma of all the preeclamptic patients 
compare to the normotensive pregnant group (4.9±0.2 ng/
mL vs. 1.9±0.54 ng/mL, p<0.001).(16)  Most of the studies 
which showed the increase of TGF-β1 concentration were 
conducted in pregnant women in their third trimester of 
pregnancy. Meanwhile, the previous study that relevant 
with our study mostly carried out in the subject in their 
second trimester of pregnancy. Whether the decrease level 
of TGF-β1  in the second trimester is responsible for the 
systemic inflammation in preeclampsia patients or the 
increased level of TGF-β1 is one of preeclampsia trigger 
or consequence of preeclampsia are still unclear. In our 
study, the mean gestational age of the subjects was 37 with 
the majority of the subjects were in their third trimester. 
However, we did not differ the subjects into the two 
trimesters so we cannot detect any difference of TGF-β1 in 
the two trimesters.  
 The inconsistent of the results may also occur because 
of many factors such as the difference in gestational age of 
the subjects, the assay techniques, the study design and the 
blood processing procedures.(9) Review of the literature 
showed that different methods and protocols were giving 
various ranges of the TGF-β1 concentration.(16) Moreover, 
maternal systemic inflammatory status and the distributions 
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of the severity of preeclampsia could also play a role in the 
dissimilarity of the finding.(15) 
 We just assessed only a single sample obtained 
during this gestational period, so how long the TGF-β1 
concentration had altered prior to the onset of preeclampsia 
cannot be determined either. It is recommended to give some 
comments on the findings which was in accordance with 
the two trimester pregnant women although the subjects of 
study were in the third trimester 
The TGF-β1 concentration was lower in pregnant women 
with preeclampsia compared to normal pregnant women. 
The TGF-β1 may play a role as a marker in preeclampsia.
Conclusion
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